Wall Street is bullish on Viking, but the company still has a lot to prove Viking has a number of different clinical studies ongoing with its lead GLP-1 candidate, VK2735, which is a dual GLP-1 ...

Right now, Novo Nordisk and Eli Lilly are the biggest players in town when it comes to treating diabetes and obesity. Viking Therapeutics has a unique candidate in its pipeline that could disrupt ...

OpenAI chief executive Sam Altman said on Friday the company has been "on the wrong side of history" regarding open source, ...

VK2735’s Phase III-ready status and plans to file an investigational New Drug (IND) application for its first amylin agonist candidate for obesity in 2025 “offers a unique set of attractive ...

Viking Therapeutics stock plunged late Wednesday on an earnings report that included mostly incremental updates for its ...